Knight Therapeutics (GUD) News Today C$5.71 +0.03 (+0.53%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider Trades All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period July 24 at 6:24 AM | finance.yahoo.comKnight Therapeutics Inc. (KHTRF)July 11, 2024 | marketbeat.comInsider Selling: Knight Therapeutics Inc. (TSE:GUD) Senior Officer Sells 10,000 Shares of StockKnight Therapeutics Inc. (TSE:GUD - Get Free Report) Senior Officer Amal Khouri sold 10,000 shares of the stock in a transaction that occurred on Thursday, July 11th. The shares were sold at an average price of C$5.70, for a total value of C$57,000.00.July 4, 2024 | insidertrades.comKnight Therapeutics Inc. (TSE:GUD) Senior Officer Amal Khouri Sells 10,000 SharesJune 15, 2024 | insidertrades.comAmal Khouri Sells 20,000 Shares of Knight Therapeutics Inc. (TSE:GUD) StockJune 13, 2024 | marketbeat.comKnight Therapeutics Inc. (TSE:GUD) Senior Officer Amal Khouri Sells 20,000 SharesKnight Therapeutics Inc. (TSE:GUD - Get Free Report) Senior Officer Amal Khouri sold 20,000 shares of the stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of C$5.80, for a total transaction of C$116,022.00.June 6, 2024 | insidertrades.comKnight Therapeutics Inc. (TSE:GUD) Director Buys C$29,000.00 in StockJune 5, 2024 | marketbeat.comInsider Buying: Knight Therapeutics Inc. (TSE:GUD) Director Buys 5,000 Shares of StockKnight Therapeutics Inc. (TSE:GUD - Get Free Report) Director Jonathan Ross Goodman bought 5,000 shares of the stock in a transaction dated Wednesday, June 5th. The stock was bought at an average cost of C$5.80 per share, for a total transaction of C$29,000.00.May 30, 2024 | insidertrades.comInsider Selling: Knight Therapeutics Inc. (TSE:GUD) Director Sells 15,000 Shares of StockMay 15, 2024 | seekingalpha.comGUD:CA Knight Therapeutics Inc.May 14, 2024 | marketbeat.comKnight Therapeutics (TSE:GUD) Reaches New 52-Week High at $6.17Knight Therapeutics (TSE:GUD) Reaches New 12-Month High at $6.17May 12, 2024 | seekingalpha.comKnight Therapeutics, Inc. (KHTRF) Q1 2024 Earnings Call TranscriptMay 10, 2024 | marketbeat.comStifel Nicolaus Increases Knight Therapeutics (TSE:GUD) Price Target to C$5.75Stifel Nicolaus lifted their price objective on shares of Knight Therapeutics from C$5.40 to C$5.75 in a research report on Friday.May 9, 2024 | insidertrades.comInsider Selling: Knight Therapeutics Inc. (TSE:GUD) Insider Sells 15,000 Shares of StockMay 6, 2024 | marketbeat.comKnight Therapeutics (TSE:GUD) Reaches New 12-Month High at $5.95Knight Therapeutics (TSE:GUD) Reaches New 12-Month High at $5.95May 3, 2024 | marketbeat.comKnight Therapeutics (GUD) to Release Quarterly Earnings on ThursdayKnight Therapeutics (TSE:GUD) will be releasing earnings before the market opens on Thursday, May 9, Zacks reports.May 1, 2024 | marketbeat.comKnight Therapeutics (TSE:GUD) PT Raised to C$5.40Stifel Nicolaus lifted their price target on shares of Knight Therapeutics from C$5.25 to C$5.40 and gave the company a "hold" rating in a research report on Wednesday.April 21, 2024 | investing.comKnight Therapeutics Inc (GUD)April 16, 2024 | msn.comTSX Healthcare in April 2024: The Best Stocks to Buy Right NowApril 16, 2024 | insidertrades.comKnight Therapeutics Inc. (TSE:GUD) Insider Sime Armoyan Sells 10,900 SharesApril 15, 2024 | marketbeat.comSime Armoyan Sells 10,900 Shares of Knight Therapeutics Inc. (TSE:GUD) StockKnight Therapeutics Inc. (TSE:GUD - Get Free Report) insider Sime Armoyan sold 10,900 shares of Knight Therapeutics stock in a transaction dated Thursday, April 11th. The stock was sold at an average price of C$5.95, for a total transaction of C$64,855.00.April 10, 2024 | marketbeat.comKnight Therapeutics (TSE:GUD) Reaches New 1-Year High at $5.80Knight Therapeutics (TSE:GUD) Hits New 1-Year High at $5.80April 9, 2024 | finance.yahoo.comKnight to Present at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceApril 9, 2024 | insidertrades.comKnight Therapeutics Inc. (TSE:GUD) Insider Buys C$32,550.00 in StockApril 8, 2024 | marketbeat.comInsider Buying: Knight Therapeutics Inc. (TSE:GUD) Insider Purchases 6,200 Shares of StockKnight Therapeutics Inc. (TSE:GUD - Get Free Report) insider Sime Armoyan bought 6,200 shares of the company's stock in a transaction on Monday, April 1st. The shares were acquired at an average price of C$5.25 per share, with a total value of C$32,550.00.March 26, 2024 | insidertrades.comKnight Therapeutics Inc. (TSE:GUD) Insider Sime Armoyan Acquires 351,000 SharesMarch 25, 2024 | marketbeat.comKnight Therapeutics Inc. (TSE:GUD) Insider Sime Armoyan Buys 351,000 SharesKnight Therapeutics Inc. (TSE:GUD - Get Free Report) insider Sime Armoyan bought 351,000 shares of the company's stock in a transaction dated Monday, March 25th. The stock was acquired at an average price of C$5.25 per share, for a total transaction of C$1,842,750.00.March 23, 2024 | investing.comEarnings call: Knight Therapeutics announced record revenues of $343 millionMarch 22, 2024 | marketbeat.comRoyal Bank of Canada Raises Knight Therapeutics (TSE:GUD) Price Target to C$7.00Royal Bank of Canada increased their price target on shares of Knight Therapeutics from C$6.50 to C$7.00 and gave the company an "outperform" rating in a research report on Friday.March 22, 2024 | finance.yahoo.comKnight Therapeutics Full Year 2023 Earnings: Misses ExpectationsMarch 20, 2024 | ca.finance.yahoo.comKnight Therapeutics Inc (04K.SG)March 14, 2024 | ca.finance.yahoo.comStocks in play: Knight Therapeutics Inc.March 8, 2024 | marketbeat.comRaymond James Research Analysts Increase Earnings Estimates for Knight Therapeutics Inc. (TSE:GUD)Knight Therapeutics Inc. (TSE:GUD - Free Report) - Research analysts at Raymond James raised their FY2026 earnings estimates for shares of Knight Therapeutics in a research report issued on Wednesday, March 6th. Raymond James analyst R. Sarugaser now anticipates that the company will post earningMarch 7, 2024 | finance.yahoo.comFavourable Signals For Knight Therapeutics: Numerous Insiders Acquired StockMarch 1, 2024 | marketbeat.comAnalysts Offer Predictions for Knight Therapeutics Inc.'s Q4 2023 Earnings (TSE:GUD)Knight Therapeutics Inc. (TSE:GUD - Free Report) - Equities researchers at Raymond James issued their Q4 2023 EPS estimates for Knight Therapeutics in a report released on Wednesday, February 28th. Raymond James analyst R. Sarugaser anticipates that the company will post earnings of $0.00 per shaFebruary 29, 2024 | ca.finance.yahoo.comStocks in play: Knight Therapeutics Inc.,February 29, 2024 | msn.comKnight Therapeutics launches Minjuvi in BrazilFebruary 29, 2024 | marketbeat.comBrokers Issue Forecasts for Knight Therapeutics Inc.'s FY2023 Earnings (TSE:GUD)Knight Therapeutics Inc. (TSE:GUD - Free Report) - Stock analysts at Raymond James issued their FY2023 earnings per share estimates for Knight Therapeutics in a research report issued on Wednesday, February 28th. Raymond James analyst R. Sarugaser anticipates that the company will post earnings pFebruary 21, 2024 | finance.yahoo.comKnight Therapeutics Announces Regulatory Submission of Fostamatinib in BrazilJanuary 23, 2024 | marketbeat.comInsider Selling: Knight Therapeutics Inc. (TSE:GUD) Insider Sells 28,200 Shares of StockKnight Therapeutics Inc. (TSE:GUD - Get Free Report) insider Sime Armoyan sold 28,200 shares of the business's stock in a transaction that occurred on Monday, January 22nd. The shares were sold at an average price of C$5.75, for a total value of C$162,150.00.January 22, 2024 | marketbeat.comKnight Therapeutics Inc. (TSE:GUD) Insider Sime Armoyan Sells 91,000 SharesKnight Therapeutics Inc. (TSE:GUD - Get Free Report) insider Sime Armoyan sold 91,000 shares of the stock in a transaction that occurred on Friday, January 19th. The shares were sold at an average price of C$5.75, for a total value of C$523,250.00.January 4, 2024 | finance.yahoo.comKnight Therapeutics Announces Product Launch for IMVEXXY® in CanadaDecember 19, 2023 | finance.yahoo.comKnight Therapeutics Enters into Exclusive License Agreement with Supernus Pharmaceuticals for Qelbree® (viloxazine) in CanadaOctober 2, 2023 | finance.yahoo.comKnight Therapeutics Inc. places No. 90 on The Globe and Mail's fifth-annual ranking of Canada's Top Growing CompaniesSeptember 14, 2023 | theglobeandmail.comClosing Bell: Knight Therapeutics Inc flat on Thursday (GUD)August 12, 2023 | markets.businessinsider.comKnight Therapeutics (KHTRF) Receives a Buy from RBC CapitalAugust 10, 2023 | theglobeandmail.comTrading For This Specialty Pharma Company is up Following Second Quarter ResultsAugust 10, 2023 | finance.yahoo.comKnight Therapeutics Reports Second Quarter 2023 ResultsAugust 3, 2023 | finance.yahoo.comNotice of Knight Therapeutics' Second Quarter 2023 Results Conference CallJune 7, 2023 | theglobeandmail.comClosing Bell: Knight Therapeutics Inc up on Tuesday (GUD)June 2, 2023 | finance.yahoo.comKnight to Present at the Jefferies 2023 Healthcare Conference in New York City Get Knight Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GUD and its competitors with MarketBeat's FREE daily newsletter. Email Address How a $0.25 cent option contract makes my top traders feel (Ad)If you don’t know me, I’ve been in the markets for over 40 years… but recently, I’ve discovered a breakthrough that might be my favorite strategy of ALL time! While I kept the finer details of these $0.25 Cent Trades under wraps until recently… Click now to see for yourself what $0.25 Cent Trades is all about GUD Media Mentions By Week GUD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GUD News Sentiment▼0.000.62▲Average Medical News Sentiment GUD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GUD Articles This Week▼10▲GUD Articles Average Week Get Knight Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GUD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: TLRY News CRON News WEED News ACB News OGI News CRDL News CPH News RX News HLS News CWEB News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (TSE:GUD) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Knight Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Knight Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
